Hikma Pharmaceuticals PLC (LON:HIK) Stock Has Consensus Target Price of GBX 2,085.83 According to Brokerages

Hikma Pharmaceuticals PLC (LON:HIK) has earned an average recommendation of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the last year is GBX 2,085.83.

A number of brokerages have issued reports on HIK. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Citigroup increased their price objective on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Berenberg Bank raised their target price on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Finally, Jefferies Financial Group restated a “buy” rating and issued a GBX 2,025 target price on shares of Hikma Pharmaceuticals in a report on Friday, September 25th.

Insider Activity

In related news, insider Tobias Hestler acquired 7,500 shares of the stock in a transaction dated Monday, August 10th. The stock was bought at an average cost of GBX 1,648 per share, with a total value of £123,600. 22.26% of the stock is owned by corporate insiders.

Hikma Pharmaceuticals Stock Performance

Hikma Pharmaceuticals stock opened at GBX 1,623 on Tuesday. The firm has a market capitalization of £3.36 billion, a P/E ratio of 9.22, a PEG ratio of 2.38 and a beta of 0.66. The stock has a fifty day moving average price of GBX 1,606.70 and a 200 day moving average price of GBX 1,493.21. Hikma Pharmaceuticals has a 52 week low of GBX 1,187 and a 52 week high of GBX 1,865. The company has a current ratio of 1.98, a quick ratio of 1.27 and a debt-to-equity ratio of 77.57.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.